biotech / news / / The Telegraph
AstraZeneca is reviving a £200m investment in its Cambridge research facility and spending a further £100m on a project in Macclesfield.
AstraZeneca is reviving its £200m Cambridge research investment and committing £100m to Macclesfield.
KEY POINTS
- This decision follows a government agreement to pay 25% more for new medicines through the NHS.
- Labour committed to cutting mandatory rebates drug companies pay on sales of newer medicines to the NHS.
- Changes were made partly to avoid US trade tariffs after pharma firms lobbied President Trump on UK pricing.
COMPANIES
Summarized by Newsio from The Telegraph. How we summarize →